These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37583964)

  • 1. Retreatment after loss to follow-up reduces mortality in patients with multidrug/rifampicin-resistant tuberculosis.
    Choi H; Mok J; Ae Kang Y; Jeong D; Kang HY; Kim HJ; Kim HS; Jeon D
    ERJ Open Res; 2023 Jul; 9(4):. PubMed ID: 37583964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of loss to follow-up among adult tuberculosis patients in Southern Ethiopia: a retrospective follow-up study.
    Watumo D; Mengesha MM; Gobena T; Gebremichael MA; Jerene D
    BMC Public Health; 2022 May; 22(1):976. PubMed ID: 35568853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low BMI increases all-cause mortality rates in patients with drug-resistant TB.
    Adamashvili N; Baliashvili D; Kuchukhidze G; Salindri AD; Kempker RR; Blumberg HM; Lomtadze N; Avaliani Z; Magee MJ
    Int J Tuberc Lung Dis; 2022 Apr; 26(4):326-333. PubMed ID: 35351237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Loss to follow-up in patients treated for multidrug-resistant tuberculosis in EcuadorA Perda de seguimento de pacientes tratados para tuberculose multirresistente a medicamentos no Equador].
    Tatés-Ortega N; Álvarez J; López L; Mendoza-Ticona A; Alarcón-Arrascue E
    Rev Panam Salud Publica; 2019; 43():e91. PubMed ID: 31892925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with unfavourable treatment outcomes among people with rifampicin-resistant tuberculosis in Armenia, 2014-2017.
    Khachatryan L; Grigoryan R; Dadu A; Kumar AMV; Akopyan K; Dumchev K; Harutyunyan H; Matteelli A
    Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isoniazid mono-resistant tuberculosis: Time to take it seriously.
    Garg K; Saini V; Dhillon R; Agarwal P
    Indian J Tuberc; 2019 Apr; 66(2):247-252. PubMed ID: 31151492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
    Espinal MA; Kim SJ; Suarez PG; Kam KM; Khomenko AG; Migliori GB; Baéz J; Kochi A; Dye C; Raviglione MC
    JAMA; 2000 May; 283(19):2537-45. PubMed ID: 10815117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and predictors of lost to follow-up among drug-resistant tuberculosis patients at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia: a retrospective follow-up study.
    Kassa GM; Teferra AS; Wolde HF; Muluneh AG; Merid MW
    BMC Infect Dis; 2019 Sep; 19(1):817. PubMed ID: 31533661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.
    Bulabula ANH; Nelson JA; Musafiri EM; Machekano R; Sam-Agudu NA; Diacon AH; Shah M; Creswell J; Theron G; Warren RM; Jacobson KR; Chirambiza JP; Kalumuna D; Bisimwa BC; Katoto PDMC; Kaswa MK; Birembano FM; Kitete L; Grobusch MP; Kashongwe ZM; Nachega JB
    Clin Infect Dis; 2019 Sep; 69(8):1278-1287. PubMed ID: 30759187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for unfavourable treatment outcomes among rifampicin-resistant tuberculosis patients in Tajikistan.
    Makhmudova M; Maxsumova Z; Rajabzoda A; Makhmadov A; van den Hof S; Mirtskhulava V
    Int J Tuberc Lung Dis; 2019 Mar; 23(3):331-336. PubMed ID: 30871664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Factors for Unfavorable Outcomes of Tuberculosis in Korea: Implications for Patient-Centered Care in Tuberculosis Treatment.
    Hong HY; Park Y; Yong SH; Woo A; Leem AY; Lee SH; Chung KS; Lee SH; Kim SY; Kim EY; Jung JY; Park MS; Kim YS; Shin SJ; Kang YA
    J Korean Med Sci; 2024 Jan; 39(2):e4. PubMed ID: 38225780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and predictors of LTFU among adults with TB/HIV co-infection in two governmental hospitals, Mekelle, Ethiopia, 2009-2016: survival model approach.
    Gezae KE; Abebe HT; Gebretsadik LG
    BMC Infect Dis; 2019 Feb; 19(1):107. PubMed ID: 30717705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Travel distance to rifampicin-resistant tuberculosis treatment and its impact on loss to follow-up: the importance of continued RR-TB treatment decentralization in South Africa.
    McNabb KC; Bergman AJ; Patil A; Lowensen K; Mthimkhulu N; Budhathoki C; Perrin N; Farley JE
    BMC Public Health; 2024 Feb; 24(1):578. PubMed ID: 38389038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of treatment outcomes in patients with multidrug-resistant TB.
    Burhan E; Soepandi PZ; Isbaniah F; Damayanti K; Edwar SQ; Maruli MF; Ralena NA; Susanto AD
    Int J Tuberc Lung Dis; 2022 Feb; 26(2):126-132. PubMed ID: 35086624
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment outcomes among children, adolescents, and adults on treatment for tuberculosis in two metropolitan municipalities in Gauteng Province, South Africa.
    Berry KM; Rodriguez CA; Berhanu RH; Ismail N; Mvusi L; Long L; Evans D
    BMC Public Health; 2019 Jul; 19(1):973. PubMed ID: 31331311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
    Pai H; Ndjeka N; Mbuagbaw L; Kaniga K; Birmingham E; Mao G; Alquier L; Davis K; Bodard A; Williams A; Van Tongel M; Thoret-Bauchet F; Omar SV; Bakare N
    BMC Infect Dis; 2022 Nov; 22(1):870. PubMed ID: 36414938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of loss to follow-up among tuberculosis patients in South Korea: whom should we focus on?
    Kim HW; Min J; Ko Y; Oh JY; Jeong YJ; Lee EH; Yang B; Koo HK; Lee SS; Park JS; Park KJ; Chang JH; Joh J; Lee MK; Kim JS
    Front Public Health; 2023; 11():1247772. PubMed ID: 37927864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High rates of death and loss to follow-up by 12 months of rifampicin resistant TB treatment in South Africa.
    Hirasen K; Berhanu R; Evans D; Rosen S; Sanne I; Long L
    PLoS One; 2018; 13(10):e0205463. PubMed ID: 30300403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment outcomes in patients with multidrug-resistant tuberculosis.
    Maier C; Chesov D; Schaub D; Kalsdorf B; Andres S; Friesen I; Reimann M; Lange C
    Clin Microbiol Infect; 2023 Jun; 29(6):751-757. PubMed ID: 36842637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nationwide Treatment Outcomes of Patients With Multidrug/Rifampin-Resistant Tuberculosis in Korea, 2011-2017: A Retrospective Cohort Study (Korean TB-POST).
    Choi H; Mok J; Kang YA; Jeong D; Kang HY; Kim HJ; Kim HS; Jeon D
    J Korean Med Sci; 2023 Feb; 38(5):e33. PubMed ID: 36747362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.